Syntaxin (United Kingdom) a preclinical-stage biopharmaceutical company focusing on targeted secretion inhibitors for the potential treatment of pain, endocrine disease and cancer, closed a $28.3M Series C financing. Participants include Lundbeckfond Ventures, Ipsen, Seventure Partners, Abingworth, SROne, Life Science Partners, Johnson & Johnson Development Corp and Quest for Growth.

Pathwork Diagnostics (Redwood City, CA) a commercial-stage molecular diagnostics company focused on tumor RNA expression patterns, closed a $30M Series C financing, it announced. Participants include Alta Partners, Abingworth, Advent Venture Partners, Novus Ventures, Prospect Venture Partners and Venrock.

Oxagen (United Kingdom) a clinical-stage biopharmaceutical company focused on asthma and allergic rhinitis based drug company focused on inflammation, closed a $25.M Series C financing. Participants include MPM Capital, SV Life Sciences, Advent Ventures, Bessemer Venture Partners, Omega Ventures, Abingworth, International Bio Trust, Red Abbey Venture Partners and Wellcome Trust.

Note: 2009 Year-in-Review Trend Analysis Coming [...]

PrimeraDx (Mansfield, MA) a development-stage molecular diagnostics company focused on automated multiplexed assays of infectious disease testing in immune compromised patients undergoing solid organ and bone marrow transplant, closed a $20M Series C financing. Participants include CHL Medical Partners, Abingworth, InterWest Partners, Malaysian Technology Development Corporation, MPM Capital, Burrill & Co. and Invus.